What does Viehbacher mean by 'reasonable'?

When CEOs on either side of a proposed buyout start using the same words, does that mean a deal is imminent? Not according to Sanofi-Aventis chief Chris Viehbacher (photo), who could have been quoting Genzyme CEO Henri Termeer yesterday at the Bank of America Merrill Lynch Global Healthcare Conference in London.

Viehbacher said he saw a "reasonable" chance of striking a deal with Genzyme. Shareholders are expecting a "reasonable" price, he said. Was it a coded message for Termeer, who last week asked for "a reasonable starting point" for negotiations?

Of course, the word "reasonable" can mean different things to different people; it's too bad neither man mentioned numbers. Viehbacher wouldn't specify just what the shareholders' expectations are, nor did Termeer say just what the right starting point might be. The only number that's public is that $69 per share price, which Sanofi's sticking to--at least for now--and Termeer dismisses completely. No wonder Viehbacher predicts the deal could take awhile.

- read the Bloomberg coverage
- check out the news from Reuters

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.